Palisade Bio (PALI) FCF Margin (2011 - 2023)

Palisade Bio's (PALI) quarterly FCF Margin came in at 1410.4% in Q1 2023, up 97.72% on a QoQ basis from 61960.0% in Q4 2020.

Palisade Bio (PALI) FCF Margin (2011 - 2023) Analysis & Trends

Palisade Bio (PALI) has 11 years of FCF Margin data on file, last reported at 1410.4% in Q1 2023.

On a quarterly basis, FCF Margin changed N/A year-over-year to 1410.4% in Q1 2023; TTM through Dec 2023 was 4453.2%, a N/A change from a year earlier, with the FY2023 full-year figure at 4454.8%, changed N/A from the prior year.
FCF Margin for Q1 2023 stood at 1410.4%, up from 61960.0% in the prior quarter.
Over the last five years, FCF Margin for PALI reached as high as 1410.4% in Q1 2023 and fell as low as 81957.28% in Q4 2019.
Historically, FCF Margin has averaged 44127.59% across 3 years, with a median of 34720.0% in 2020.
Across the five-year window, FCF Margin tumbled 1953800 bps in 2019 and soared 4116960 bps in 2020, its largest moves.
Year by year, FCF Margin stood at 81957.28% in 2019, then advanced by 24 bps to 61960.0% in 2020, then jumped by 98 bps to 1410.4% in 2023.
Per Business Quant data, the three most recent FCF Margin figures were 1410.4% in Q1 2023, 61960.0% in Q4 2020, and 34720.0% in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	10.45%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	43.35%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	23.53%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Palisade Bio	985.76	-132.63 Mn	-	-

Download Data